Nimotop (Nimodipine)

Nimodipine is an L‑type calcium channel antagonist. By blocking calcium entry into the smooth muscle cells of cerebral arteries, it causes selective vasodilation of intracerebral vessels, thereby increasing cerebral perfusion and reducing the risk of vasospasm after bleeding into the subarachnoid space.

The exact dose of Nimotop is determined by the prescribing physician based on the individual patient's condition and clinical guidelines. Typically, the medication is administered orally as a tablet taken twice daily, but the prescriber’s specific order should always be followed.

Safety data for nimodipine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Nimotop, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required cold‑chain handling) and the necessary import documentation.

Nimodipine is specifically designed to cross the blood‑brain barrier, providing targeted cerebral vasodilation, whereas many other dihydropyridine calcium channel blockers such as amlodipine primarily affect systemic vascular beds and are not indicated for preventing cerebral vasospasm. This pharmacokinetic property makes nimodipine the preferred choice for neurovascular indications.

Nimotop tablets should be stored at ambient temperature below 25 °C, in the original blister pack, protected from moisture, light and heat. Keep the medication out of reach of children and do not use it after the printed expiry date.

Nimotop is taken orally as a whole tablet, usually with or without food as directed by the prescriber. Swallow the tablet with a glass of water; do not crush, chew, or split the tablet unless specifically instructed by a healthcare professional.

Serious adverse reactions can include severe hypotension, myocardial infarction, cardiac arrhythmias, hepatic dysfunction, and allergic reactions such as Stevens‑Johnson syndrome or anaphylaxis. Patients should seek immediate medical attention if they experience chest pain, fainting, unexplained rash, jaundice, or any sudden change in health status.

Nimotop should be avoided in individuals with known hypersensitivity to nimodipine or other dihydropyridine calcium channel blockers, patients with severe hypotension, and those taking contraindicated vasodilators. Caution is also advised for patients with significant liver impairment, and the drug should be used only under medical supervision in such cases.